Results 191 to 200 of about 54,679 (264)

Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success ...
Keiko Yamamoto, Aya Iwase, Hideki Maeda
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

Cancer
Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, Gui C, Du Q, Liu J.   +8 more
europepmc   +1 more source

Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study

European Journal of Neurology, Volume 33, Issue 6, June 2026.
In a cohort of 2043 patients treated with immune checkpoint inhibitors (ICI), severe neurological immune‐related adverse events (n‐irAEs) occurred in 0.5% of cases. These events predominantly involved the peripheral nervous system (PNS) and showed variable onset.
Anna Grisold, Angelika M. Starzer, Sara Silvaieh, Martin Krenn, Marie‐Bernadette Aretin, Manuela Schmidinger, Julia M. Ressler, Stephan Polterauer, Thomas Berger, Matthias Preusser, Anna S. Berghoff   +10 more
wiley   +1 more source

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. [PDF]

J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G.   +19 more
europepmc   +1 more source

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). [PDF]

Oncologist
Mandl A, Chen R, Das S, Strosberg JR, Kasi A, Konda B, Li D, Burns TF, Chauhan A, Ciombor KK, Dayyani F, Dorff T, Ohr JP, Patel BB, Sukrithan V, Soares HP, Chen K, Liu SV, Tesfaye AA, Carducci MA, Beumer JH.   +20 more
europepmc   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 1069-1077, June 2026.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. [PDF]

Clin Cancer Res
Guercio BJ, Pietzak EJ, Ravichandran V, Chen JF, Shah RH, Peters V, Regazzi AM, Niglio SA, Aggen DH, Funt SA, Donahue TF, Goh AC, Cha EK, Wong P, Richards AL, Cobbs CC, Donat SM, Dalbagni G, Bochner BH, Iyer G, Donoghue MTA, Ostrovnaya I, Al-Ahmadie HA, Rosenberg JE, Teo MY.   +24 more
europepmc   +1 more source

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer. [PDF]

J Cardiovasc Pharmacol
Quagliariello V, Passariello M, Belardo M, Esposito A, Paone M, Berretta M, Iovine M, Barbato M, Canale ML, Paccone A, Inno A, Oliva S, Maurea C, Forte P, Mauriello A, Fonderico C, Gallucci G, Tarantini L, Camilli M, Camerini A, De Lorenzo C, Maurea N.   +21 more
europepmc   +1 more source

Role of CTLA-4 blockade and dacarbazine therapy following anti-PD-1 resistance in melanoma. [PDF]

Discov Oncol
Urbonas V, Dulskas A.
europepmc   +1 more source

A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma. [PDF]

Front Immunol
Palacka P, Málek T, Makovník M, Felediová R, Rychlý B, Kolníková G.   +5 more
europepmc   +1 more source